JP Morgan Chase
CRSP icon

JP Morgan Chase’s CRISPR Therapeutics CRSP Stock Holding History

JP Morgan Chase’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.6M Sell
431,669
-25,970
-6% -$1.37M ﹤0.01% 2040
2026
Q1 		$20.3M Sell
457,639
-85,315
-16% -$4.5M ﹤0.01% 2056
2025
Q4 		$28.5M Sell
542,954
-50,462
-9% -$3.02M ﹤0.01% 1758
2025
Q3 		$38.5M Buy
593,416
+272,322
+85% +$15.6M ﹤0.01% 1583
2025
Q2 		$15.6M Buy
321,094
+25,107
+8% +$972K ﹤0.01% 2149
2025
Q1 		$10.1M Buy
295,987
+6,810
+2% +$289K ﹤0.01% 2539
2024
Q4 		$11.4M Sell
289,177
-65,065
-18% -$3.07M ﹤0.01% 2573
2024
Q3 		$16.6M Buy
354,242
+25,173
+8% +$1.28M ﹤0.01% 2152
2024
Q2 		$17.8M Sell
329,069
-63,681
-16% -$3.68M ﹤0.01% 1964
2024
Q1 		$26.8M Sell
392,750
-70,520
-15% -$5.05M ﹤0.01% 1694
2023
Q4 		$29M Sell
463,270
-57,159
-11% -$3.16M ﹤0.01% 1554
2023
Q3 		$23.6M Sell
520,429
-30,966
-6% -$1.6M ﹤0.01% 1556
2023
Q2 		$31M Sell
551,395
-31,269
-5% -$1.77M ﹤0.01% 1384
2023
Q1 		$26.4M Sell
582,664
-6,959
-1% -$338K ﹤0.01% 1469
2022
Q4 		$24M Sell
589,623
-23,267
-4% -$1.23M ﹤0.01% 1527
2022
Q3 		$40.1M Sell
612,890
-50,170
-8% -$3.64M 0.01% 1151
2022
Q2 		$40.3M Buy
663,060
+16,488
+3% +$969K 0.01% 1164
2022
Q1 		$40.6M Sell
646,572
-125,327
-16% -$7.87M ﹤0.01% 1277
2021
Q4 		$58.5M Buy
771,899
+127,313
+20% +$11.1M 0.01% 1134
2021
Q3 		$72.2M Buy
644,586
+71,245
+12% +$8.95M 0.01% 1014
2021
Q2 		$92.8M Buy
573,341
+22,931
+4% +$2.79M 0.01% 936
2021
Q1 		$67.1M Buy
550,410
+98,750
+22% +$14.9M 0.01% 1042
2020
Q4 		$69.2M Buy
451,660
+44,845
+11% +$5.3M 0.01% 940
2020
Q3 		$34.6M Buy
406,815
+159,481
+64% +$14.1M 0.01% 1162
2020
Q2 		$18.2M Buy
247,334
+52,719
+27% +$3.08M ﹤0.01% 1429
2020
Q1 		$8.25M Sell
194,615
-44,014
-18% -$2.27M ﹤0.01% 1887
2019
Q4 		$14.5M Buy
238,629
+234,025
+5,083% +$12.8M ﹤0.01% 1814
2019
Q3 		$188K Sell
4,604
-126,933
-96% -$6.07M ﹤0.01% 4660
2019
Q2 		$5.97M Buy
131,537
+127,333
+3,029% +$5.09M ﹤0.01% 2495
2019
Q1 		$151K Sell
4,204
-47,553
-92% -$1.64M ﹤0.01% 4736
2018
Q4 		$1.48M Sell
51,757
-268,726
-84% -$9.34M ﹤0.01% 3493
2018
Q3 		$14.2M Buy
320,483
+267,672
+507% +$14M ﹤0.01% 1912
2018
Q2 		$3.1M Buy
+52,811
New +$3.01M ﹤0.01% 3067
2018
Q1 		– Sell
-107,444
Closed -$2.52M – 5422
2017
Q4 		$2.52M Buy
107,444
+76,787
+250% +$1.46M ﹤0.01% 3176
2017
Q3 		$536K Buy
+30,657
New +$556K ﹤0.01% 3804

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

JP Morgan Chase's CRSP Position: Q2 2026 in Review

JP Morgan Chase reduced its CRISPR Therapeutics (CRSP) stake by 5.7% in Q2 2026, selling an estimated $1.37M and leaving 431,669 shares worth $24.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2040.

JP Morgan Chase first reported a position in CRSP in Q3 2017 and has held it in 35 quarters since. The position peaked at $92.8M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • JP Morgan Chase held 431,669 shares of CRISPR Therapeutics worth $24.6M as of Q2 2026.
  • JP Morgan Chase sold 25,970 CRISPR Therapeutics shares in Q2 2026, an estimated $1.37M.
  • CRISPR Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2040 holding.
  • JP Morgan Chase first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 35 quarters since.
  • JP Morgan Chase's CRISPR Therapeutics position peaked at $92.8M in Q2 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.